Heart drug nicorandil tested as new arthritis treatment
NCT ID NCT07516769
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether nicorandil, a drug usually used for heart conditions, can reduce inflammation and improve symptoms in people with active rheumatoid arthritis. 46 participants will take nicorandil tablets for 3 months. Researchers will measure joint disease activity and physical function to see if the drug helps.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Nicorandil (oral tablet)
- What this could lead to
- If it works, this could point toward a new treatment option for rheumatoid arthritis that reduces inflammation and improves daily function.
- What could go wrong
- This is a small early-phase trial with only 46 people, so results may not apply widely. Nicorandil is not a standard arthritis drug, and its safety and effectiveness are still unproven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHUMATOID ARTHISIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tanta university
RECRUITINGTanta, Gharbia Governorate, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.